The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms

Jürgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, Umberto Gianelli, Naseema Gangat, Alessandro M. Vannucchi, Tiziano Barbui, Daniel A. Arber, Ayalew Tefferi

Research output: Contribution to journalReview articlepeer-review

Abstract

A group of international experts, including hematopathologists, oncologists, and geneticists were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World Health Organization classification system for hematopoietic tumors. After careful deliberation, the group introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. This current in-depth review focuses on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs): essential thrombocythemia, polycythemia vera, primary myelofibrosis, and MPN, unclassifiable. The ICC MPN subcommittee chose to preserve the primary role of bone marrow morphology in disease classification and diagnostics, while also acknowledging the complementary role of genetic markers for establishing clonality, facilitating MPN subtype designation, and disease prognostication.

Original languageEnglish (US)
Pages (from-to)166-179
Number of pages14
JournalAmerican journal of hematology
Volume98
Issue number1
DOIs
StatePublished - Jan 2023

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this